Mobidiag develops and markets molecular diagnostics for Gastrointestinal Infections, Antimicrobial Resistance Management, Healthcare Associated Infection, Respiratory Infections, and shortly Sepsis. We aim at providing a global solution to clinicians suited for their own laboratory needs and capacities.
Following the COVID-19 crisis, we have harnessed our existing technologies and expertise to rapidly develop and supply two coronavirus molecular diagnostic solutions: Amplidiag® COVID-19 (for batch testing) and Novodiag® COVID-19 (for on-demand testing).
To prepare for the next flu season, Mobidiag is developing new tests for simultaneous detection of COVID-19, Influenza A, Influenza B and RSV.
How many organisations/clients currently utilise the service/solution across the UK?
Is there anything you would like to make delegates aware of ahead of the Managing Deteriorating Conditions Conference on 12th October?
We are currently offering two coronavirus molecular diagnostic automated solutions: Amplidiag® COVID-19 (for batch testing) and Novodiag® COVID-19 (for on-demand testing).
To prepare for the next flu season, Mobidiag is developing new combo tests (RESP-4) for simultaneous detection of COVID-19, Influenza A, Influenza B and RSV.
What do you feel are the key points delegates need to digest when considering a partnership with your organisation?
The extremely versatile product offer, the flexibility of the technologies used, and the internal expertise of the Mobidiag team allow great responsiveness in the development of new products in emergency situations. Rapid molecular diagnostics of coronavirus infection currently offered by Mobidiag in the case of the COVID-19 pandemic are a perfect example. We are currently putting all our efforts to secure supply chain and manufacturing capabilities to answer growing demand.
Do you want to add any other key points?
Additionally, we are supplying our other existing molecular tests, including detection of antibiotic resistances, and developing Sepsis solutions.